link.springer.com

Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma - Medical Oncology

  • ️Xu, Cong
  • ️Thu Jan 04 2024

  • Kim IH, Kim K, Rhee SG. Induction of an antioxidant protein of Saccharomyces cerevisiae by O2, Fe3+, or 2-mercaptoethanol. Proc Natl Acad Sci USA. 1989;86(16):6018–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim K, Kim IH, Lee KY, et al. The isolation and purification of a specific “protector” protein which inhibits enzyme inactivation by a thiol/Fe(III)/O2 mixed-function oxidation system. J Biol Chem. 1988;263(10):4704–11.

    Article  CAS  PubMed  Google Scholar 

  • Chae HZ, Chung SJ, Rhee SG. Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem. 1994;269(44):27670–8.

    Article  CAS  PubMed  Google Scholar 

  • Chae HZ, Robison K, Poole LB, et al. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA. 1994;91(15):7017–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hall A, Nelson K, Poole LB, et al. Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins. Antioxid Redox Signal. 2011;15(3):795–815.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rhee SG, Woo HA, Kil IS, et al. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem. 2012;287(7):4403–10.

    Article  CAS  PubMed  Google Scholar 

  • Rhee SG, Kang SW, Chang TS, et al. Peroxiredoxin, a novel family of peroxidases,". IUBMB Life. 2001;52(1–2):35–41.

    Article  CAS  PubMed  Google Scholar 

  • Wood ZA, Schroder E, Robin HJ, et al. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  • Choi H, Chang JW, Jung YK. Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase,". Cell Death Differ. 2011;18(3):405–14.

    Article  CAS  PubMed  Google Scholar 

  • Choi JH, Kim TN, Kim S, et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002;22(6A):3331–5.

    CAS  PubMed  Google Scholar 

  • Chua PJ, Lee EH, Yu Y, et al. Silencing the peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol. 2010;36(2):359–64.

    CAS  PubMed  Google Scholar 

  • Choi MH, Lee IK, Kim GW, et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature. 2005;435(7040):347–53.

    Article  CAS  PubMed  Google Scholar 

  • Chung-man HJ, Zheng S, Comhair SA, et al. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res. 2001;61(23):8578–85.

    Google Scholar 

  • Cao Z, Lindsay JG. The peroxiredoxin family: an unfolding story. Subcell Biochem. 2017;83:127–47.

    Article  CAS  PubMed  Google Scholar 

  • Cox AG, Pullar JM, Hughes G, et al. Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. Free Radic Biol Med. 2008;44(6):1001–9.

    Article  CAS  PubMed  Google Scholar 

  • Kitson SJ, Bafligil C, Ryan N, et al. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: a cohort study. Eur J Cancer. 2020;136:169–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  • Sadeghi A, Sadeghian M, Nasiri M, et al. Carbohydrate quantity and quality affect the risk of endometrial cancer: a systematic review and dose-response meta-analysis. Clin Nutr. 2020;39(6):1681–91.

    Article  CAS  PubMed  Google Scholar 

  • Cui YQ, Xiang Y, Meng F, et al. ALDH2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model. Aging (Albany NY). 2021;13(20):23588–602.

    Article  CAS  PubMed  Google Scholar 

  • Wu J, Zhou X, Ren J, et al. Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma. Comput Biol Med. 2023;163: 107164.

    Article  CAS  PubMed  Google Scholar 

  • He K, Li J, Huang X, et al. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma. Front Oncol. 2023;13:1090779.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Qu X, Li L, et al. Integrative analysis reveals a nine TP53 pathway-related lncRNA prognostic signature in endometrial cancer. Biomed Res Int. 2022;2022:5432806.

    Article  PubMed  PubMed Central  Google Scholar 

  • Jiang F, Jiang S, Cao D, et al. Immunologic signatures across molecular subtypes and potential biomarkers for sub-stratification in endometrial cancer. Int J Mol Sci. 2023;24(2):1791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu X, Ma H, Ma L, et al. The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma. Bioengineered. 2022;13(3):5525–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chow RD, Michaels T, Bellone S, et al. Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma. Cancer Discov. 2023;13(2):312–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 2019;5(10):1504–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fujii J, Ikeda Y, Kurahashi T, et al. Physiological and pathological views of peroxiredoxin 4. Free Radic Biol Med. 2015;83:373–9.

    Article  CAS  PubMed  Google Scholar 

  • Szeliga M. Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma. Neurochem Int. 2022;153: 105256.

    Article  CAS  PubMed  Google Scholar 

  • Karpenko IL, Valuev-Elliston VT, Ivanova ON, et al. Peroxiredoxins-The underrated actors during virus-induced oxidative stress. Antioxidants (Basel). 2021;10(6):977.

    Article  CAS  PubMed  Google Scholar 

  • Zhou F, Chen F, Ouyang Z, et al. Functions of peroxiredoxins and their roles in autoimmune diseases. Antioxid Redox Signal. 2023. https://doi.org/10.1089/ars.2022.0139.

    Article  PubMed  Google Scholar 

  • Drago L, Ferro D, Bakiu R, et al. Typical 2-Cys peroxiredoxins as a defense mechanism against metal-induced oxidative stress in the solitary ascidian Ciona robusta. Antioxidants (Basel). 2021;11(1):93.

    Article  PubMed  Google Scholar 

  • Picou F, Vignon C, Debeissat C, et al. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv. 2019;3(24):4271–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ambruso DR, Ellison MA, Thurman GW, et al. Peroxiredoxin 6 translocates to the plasma membrane during neutrophil activation and is required for optimal NADPH oxidase activity. Biochim Biophys Acta-Mol Cell Res. 2012;1823:306–15.

    Article  CAS  Google Scholar 

  • Ummanni R, Barreto F, Venz S, et al. Peroxiredoxins 3 and 4 Are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res. 2012;11(4):2452–66.

    Article  CAS  PubMed  Google Scholar 

  • Wang G, Zhong WC, Bi YH, et al. The prognosis of peroxiredoxin family in breast cancer. Cancer Manag Res. 2019;11:9685–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang H, Wu L, Mishra M, et al. Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy. Am J Cancer Res. 2014;4(5):445–60.

    PubMed  PubMed Central  Google Scholar 

  • Huang CY, Lee KC, Tung SY, et al. 2D-DIGE-MS proteomics approaches for identification of gelsolin and peroxiredoxin 4 with lymph node metastasis in colorectal cancer. Cancers. 2022;14(13):3189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kobayashi S, Hiwasa T, Arasawa T, et al. Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library. Oncotarget. 2018;9(26):18559–69.

    Article  PubMed  PubMed Central  Google Scholar 

  • Park SY, Lee YJ, Park J, et al. PRDX4 overexpression is associated with poor prognosis in gastric cancer. Oncol Lett. 2020;19(5):3522–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Guo X, Noguchi H, Ishii N, et al. The association of peroxiredoxin 4 with the initiation and progression of hepatocellular carcinoma. Antioxid Redox Signal. 2019;30(10):1271–84.

    Article  CAS  PubMed  Google Scholar 

  • Kim TH, Song J, Alcantara LS, et al. Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. PLoS ONE. 2012;7(8): e42818.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hintsala HR, Soini Y, Haapasaari KM, et al. Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment. Histopathology. 2015;67(3):348–57.

    Article  PubMed  Google Scholar 

  • Pedro NF, Biselli JM, Maniglia JV, et al. Candidate biomarkers for oral squamous cell carcinoma: differential expression of oxidative stress-related genes. Asian Pac J Cancer Prev. 2018;19(5):1343–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jain P, Dvorkin-Gheva A, Mollen E, et al. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Sci Adv. 2021. https://doi.org/10.1126/sciadv.abf7114.

    Article  PubMed  PubMed Central  Google Scholar 

  • Aihaiti Y, Tuerhong X, Zheng HS, et al. Peroxiredoxin 4 regulates tumor-cell-like characteristics of fibroblast-like synoviocytes in rheumatoid arthritis through PI3k/Akt signaling pathway. Clini Immunol. 2022;237:108964.

    Article  CAS  Google Scholar 

  • Song IS, Jeong YJ, Seo YJ, et al. Peroxiredoxin 3 maintains the survival of endometrial cancer stem cells by regulating oxidative stress. Oncotarget. 2017;8(54):92788–800.

    Article  PubMed  PubMed Central  Google Scholar 

  • Byun JM, Kim SS, Kim KT, et al. Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett. 2018;15(4):5111–8.

    PubMed  PubMed Central  Google Scholar 

  • Ma H, Han F, Yan X, et al. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway. J Cell Physiol. 2021;236(4):2767–81.

    Article  CAS  PubMed  Google Scholar 

  • Han Z, Li L, Huang Y, et al. "PBK/TOPK: a therapeutic target worthy of attention. Cells. 2021;10(2):371.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang H, Lee MH, Liu K, et al. PBK/TOPK: an effective drug target with diverse therapeutic potential. Cancers (Basel). 2021;13(9):2232.

    Article  CAS  PubMed  Google Scholar 

  • Gao H, Sun B, Fu H, et al. PDIA6 promotes the proliferation of HeLa cells through activating the Wnt/beta-catenin signaling pathway. Oncotarget. 2016;7(33):53289–98.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bai Y, Liu X, Qi X, et al. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway. EBioMedicine. 2019;42:311–25.

    Article  PubMed  PubMed Central  Google Scholar